Vilket är priset för Homology Medicines, Inc. (FIXX)

Priset för Homology Medicines, Inc. (FIXX) är $0.9347

Vilket är marknadsvärdet för Homology Medicines, Inc. (FIXX)

Marknadsvärdet för Homology Medicines, Inc. (FIXX) är $300.42K

Homology Medicines, Inc. (FIXX) Vinst

Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.

År	Vinst	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Vinst

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Företag

Vinst

Skillnad i vinst

Land